Entera Bio's Fiscal 2025 10-K Shows $0.042M Revenue, $0.25 Loss Per Share
ENTX sits 20% above its 52-week low of $0.98.
Summary
Entera Bio Ltd. filed its annual 10-K report for fiscal 2025, disclosing revenues of $0.042 million and a net loss of $11.439 million, resulting in a loss per share of $0.25. These financial results, which include a decline in revenue from the prior year, reflect the company's continued investment in clinical development and its profile as a development-stage biotech operating at a significant loss. This financial update provides crucial context to the recent positive news regarding the acceleration of its lead drug candidate, EB613, and a new FDA framework. Traders will need to consider the company's financial health and cash burn rate alongside its pipeline progress.
At the time of this announcement, ENTX was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.8M. The 52-week trading range was $0.98 to $3.22. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.